Adjoint Intra-operative Confocal Laser Endomicroscopy (CLE) to Present Tissue on the Cellular Level in Defined Lesions of the Central Nervous System (CNS) During Medically Induced Neurosurgery in Subcranial Tumors and Glioma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cerebral Tumors
- Sponsor
- Charalampaki, Cleopatra, M.D.
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- post-surgery comparison of in-vivo tissue characterization with ex-vivo histocytopathology
- Status
- Terminated
- Last Updated
- 7 years ago
Overview
Brief Summary
Purpose of the study is to answer the question whether confocal laser endomicroscopy (CLE, also named 'optical biopsy') might improve the results of medically necessary neurosurgery to prove practicability, safety and harmlessness of CLE during neurosurgical procedures
Detailed Description
In patients requiring neurosurgical oncological Intervention using endoscopic devices, a mini laser probe will be administered through the endoscopic device to characterize in vivo the tissue by thousandfold magnification down to the cellular level (so-called optical biopsy). Magnification is presented to the neurosurgeon in time to better differentiate between healthy and pathological tissue. Post-surgery results of in-vivo Differentiation will then be compared to histocytopathological findings.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients administered to the department of neurosurgery requiring neurosurgery due to either diagnosed gliomata (40 patients) or diagnosed subcranial tumors adjacent to or already invading neuronal structures (20 patients)
- •patients having given informed consent
Exclusion Criteria
- •severe concomitant diseases probably negatively influencing the participation in this clinical trial
- •cardial infarction or stroke within the preceding 12 months
- •Treatment resistant hypertonus (systolic blood pressure \>200 mmHg or diastolic blood pressure \>120 mmHg or a combination of both
- •Pulmonic diseases that might result in an advanced risk for anesthetic measurements
- •Patients being vaccinated with live vaccines (14 days Prior) or contra Influenza (7 days Prior) to start of the study
- •All concomitant findings that might increase in the eyes of the investigator the risk of participation
Outcomes
Primary Outcomes
post-surgery comparison of in-vivo tissue characterization with ex-vivo histocytopathology
Time Frame: duration of hospital stay, an expected average of 7 days
Secondary Outcomes
- proof of complete removal of pathologic tissue within healthy tissue(during surgical procedure, an expected average time of three hours)
- optimal tumour remission or reduction after 3 months post-surgery proven by respective diagnostic measurements(3 months post surgery)
- Composite measure of missing iatrogenic damage of healthy neuronal structures and preservation of functionality of healthy tissue(individual post-surgery controls, an expected average of up to 7 days)